BC Extra | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...
BioCentury | Mar 2, 2018
Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
BioCentury | Feb 10, 2017
Emerging Company Profile

Improving the original immunotherapy

Recombinant IL-2 was one of the first immunotherapies marketed for cancer but is not widely used due to severe off-target toxicities. Cue Biopharma Inc. is developing preclinical programs that deliver IL-2 only to T cells...
BC Innovations | Dec 20, 2016
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest IL-2 complexed with an anti-IL-2 antibody could help treat metastatic melanoma. In cell-based assays, the antibody blocked CD25 binding to IL-2 and prevented expansion of CD25-positive Tregs,...
BC Innovations | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
Items per page:
1 - 5 of 5